Alberto Auricchio, MD is Professor of Medical Genetics at the Department of Advanced Biomedicine, “Federico II” University in Naples, and Coordinator of the Molecular Therapy Program at Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli (NA), Italy. His research is focused on gene therapy of retinal and metabolic diseases using adeno-associated viral vectors. His group has contributed to the phase I/II clinical trial of Luxturna, the first approved gene therapy drug for an ocular disease, and to the development of gene therapy for mucopolysaccharidosis VI up to an ongoing phase I/II trial.
Prof. Auricchio is co-author of more than 130 peer-reviewed publications on international scientific journals and inventor of several international patents on the use of viral vectors for gene therapy. He is a member of the editorial boards of Molecular Therapy, EMBO Molecular Medicine and Translational Vision Science and Technology.
In 2006 Prof. Auricchio has received the Outstanding New Investigator Award of the American Society of Gene Therapy and in 2007 has been nominated “Cavaliere of the Italian Republic” by the President of the Italian Republic. In 2011 and 2016 Prof. Auricchio received the Consolidator and Advanced Grants, respectively, from the European Research Council.